Avidity Partners Management LP Nuvation Bio Inc. Transaction History

Avidity Partners Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.24 - $5.85 $19 - $35	-6 Reduced -0.0%	4,855,000 $15.7 Million
Q1 2022 May 16, 2022	SELL	$4.6 - $8.83 $11.6 Million - $22.3 Million	-2,527,482 Reduced 34.24%	4,855,006 $25.5 Million
Q4 2021 Feb 14, 2022	BUY	$7.75 - $10.05 $922,250 - $1.2 Million	119,000 Added 1.64%	7,382,488 $62.8 Million
Q3 2021 Nov 15, 2021	BUY	$7.78 - $10.0 $2.31 Million - $2.97 Million	297,112 Added 4.26%	7,263,488 $72.2 Million
Q2 2021 Aug 16, 2021	SELL	$9.22 - $14.48 $5.12 Million - $8.04 Million	-555,565 Reduced 7.39%	6,966,376 $64.9 Million
Q1 2021 May 17, 2021	BUY	$9.0 - $14.57 $67.7 Million - $110 Million	7,521,941 New	7,521,941 $78.6 Million

158

157M

3.2K

98.7K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $613M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.